T cell-based gene therapy of cancer

Translational Research

Volumn 161, Issue 4, 2013, Pages 365-379

  Gill, Saar ^a   Kalos, Michael ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CD19 ANTIGEN; CD20 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FOLATE RECEPTOR; LENTIVIRUS VECTOR; LYMPHOCYTE ANTIGEN RECEPTOR; MELAN A; MEMBRANE ANTIGEN; NERVE CELL ADHESION MOLECULE L1; NY ESO 1 ANTIGEN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; CELL BASED GENE THERAPY; CELL EXPANSION; COMPARATIVE STUDY; CYTOKINE RELEASE SYNDROME; DNA SEQUENCE; DNA TRANSFER; ELECTROPORATION; FOLLICULAR LYMPHOMA; GENETIC MANIPULATION; GENETIC TRANSFECTION; HISTOCOMPATIBILITY COMPLEX; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INFUSION RELATED REACTION; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LYMPHOCYTE SUBPOPULATION; MELANOMA; MEMORY T LYMPHOCYTE; NEOPLASM; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH17 CELL; TRANSGENE; TRANSIENT EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR LYSIS SYNDROME;

EID: 84875151508     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2012.11.002     Document Type: Review

References (153)

1. S. Gill, and D.L. Porter Reduced-intensity hematopoietic stem cell transplants for malignancies: harnessing the graft-versus-tumoreEffect Ann Rev Med 64 2013 101 117
2. L. Baitsch, P. Baumgaertner, and E. Devêvre Exhaustion of tumor-specific CD8 + T cells in metastases from melanoma patients J Clin Invest 3 2011 23 25
3. J. Galon, A. Costes, and F. Sanchez-Cabo Type, density, and location of immune cells within human colorectal tumors predict clinical outcome Science (New York, NY) 313 2006 1960 1964
4. J. Lustgarten, A.L. Dominguez, and C. Cuadros The CD8+ T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity Eur J Immunol 34 2004 752 761
5. L. Zhang, J.R. Conejo-Garcia, and D. Katsaros Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer N Engl J Med 348 2003 203 213
6. M. Bendandi Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures Nat Rev Cancer 9 2009 675 681
7. M. Kalos Tumor antigen-specific T cells and cancer immunotherapy: current issues and future prospects Vaccine 21 2003 781 786
8. T. Tanimoto, A. Hori, and M. Kami Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 1966 author reply 1967-8
9. D.M. Pardoll The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 12 2012 252 264
10. T. Law, R. Motzer, and M. Mazumdar Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma Cancer 76 1995 824 832
11. S. Rosenberg, M. Lotze, and L. Muul Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer New Engl J Med 313 1985 1485 1492
12. S.A. Rosenberg, and M.E. Dudley Adoptive cell therapy for the treatment of patients with metastatic melanoma Curr Opin Immunol 21 2009 233 240
13. C.H. June Science in medicine Adoptive T cell therapy for cancer in the clinic J Clin Invest 117 2007 1466 1476
14. M. Kalos Muscle CARs and TcRs: turbo-charged technologies for the (T cell) masses Cancer Immunol Immunother CII 61 2012 127 135
15. T.M. Clay, M.C. Custer, and J. Sachs Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity J Immunol 163 1999 507 513
16. L.J.N. Cooper, M. Kalos, and A. Deborah Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T J Virol 74 2000 8207 8212
17. P.F. Robbins, R.A. Morgan, and S.A. Feldman Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1 J Clin Oncol 29 2011 917 924
18. A. Varela-Rohena, P.E. Molloy, and S.M. Dunn Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor Nat Med 14 2008 1390 1395
19. L.A. Johnson, R.A. Morgan, and M.E. Dudley Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen Blood 114 2009 535 546
20. R.A. Morgan, M.E. Dudley, and J.R. Wunderlich Cancer regression in patients after transfer of genetically engineered lymphocytes Science (New York, NY) 314 2006 126 129
21. M.A. Pule, B. Savoldo, and G.D. Myers Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma Nat Med 14 2008 1264 1270
22. B.G. Till, M.C. Jensen, and J. Wang Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells Blood 112 2008 2261 2271
23. B. Jena, G. Dotti, and L.J.N. Cooper Review article redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor Blood 116 2010 1035 1044
24. Amir AL, Steen DM van der, Loenen MM van, et al. PRAME-specific Allo-HLA-restricted T cells with potent antitumor reactivity useful for therapeutic T-cell receptor gene transfer. Clin Cancer Res 2011;17:5615-25.
25. R.S. Friedman, A.G. Spies, and M. Kalos Identification of naturally processed CD8 T cell epitopes from prostein, a prostate tissue-specific vaccine candidate Eur J Immunol 34 2004 1091 1101
26. A.S. Chervin, D.H. Aggen, J.M. Raseman, and D.M. Kranz Engineering higher affinity T cell receptors using a T cell display system J Immunol Methods 339 2008 175 184
27. Y. Li, R. Moysey, and P.E. Molloy Directed evolution of human T-cell receptors with picomolar affinities by phage display Nat Biotechnol 23 2005 349 354
28. P.F. Robbins, Y.F. Li, and M. El-gamil Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions J Immunol 180 2008 6116 6131
29. J. Kuball, B. Hauptrock, and V. Malina Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain J Exp Med 206 2009 463 475
30. Y. Zhao, A.D. Bennett, and Z. Zheng CD4+ T cells with the ability to recognize and kill tumor J Immunol 179 2007 5845 5854
31. J. Kuball, M.L. Dossett, and M. Wolfl Facilitating matched pairing and expression of TCR chains introduced into human T cells Blood 109 2007 2331 2338
32. G. Gross, T. Waks, and Z. Eshhar Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity Proc Nat Acad Sci U S A 86 1989 10024 10028
33. M.C. Milone, J.D. Fish, and C. Carpenito Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo Mol Ther 17 2009 1453 1464
34. M. Sadelain, R. Brentjens, and I. Rivie The promise and potential pitfalls of chimeric antigen receptors Curr Opin Immunol 21 2009 215 223
35. L. Novellino, C. Castelli, and G. Parmiani A listing of human tumor antigens recognized by T cells: March 2004 update Cancer Immunol Immunother CII 54 2005 187 207
36. O.L. Caballero, and Y.-T. Chen Cancer/testis (CT) antigens: potential targets for immunotherapy Cancer Sci 100 2009 2014 2021
37. L.J. Old Cancer vaccines: an overview Cancer Immun 8 2008 1 8
38. M.R. Parkhurst, J.C. Yang, and R.C. Langan T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis Mol Ther 19 2011 620 626
39. R.J. Brentjens, I. Rivière, and J.H. Park Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias Blood 2011 4817 4828
40. J.N. Kochenderfer, M.E. Dudley, and S.A. Feldman B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells Blood 119 2012 2709 2720
41. D.L. Porter, B.L. Levine, M. Kalos, A. Bagg, and C.H. June Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia N Engl J Med 365 2011 725 733
42. M. Kalos, B.L. Levine, and D.L. Porter T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia Sci Transl Med 3 2011 95ra73-95ra73
43. S.M. Amos, C.P.M. Duong, and J.A. Westwood Autoimmunity associated with immunotherapy of cancer Blood 118 2011 499 509
44. L. Naldini, U. Blömer, and P. Gallay In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector Science 272 1996 263 267
45. R.G. Amado, and I.S.Y. Chen Lentiviral vectors-the promise of gene therapy within reach? Science 285 1999 674 676
46. J. Ellis Silencing and variegation of gammaretrovirus and lentivirus vectors Hum Gene Ther 16 2005 1241 1246
47. D. Wolf, and S.P. Goff Host restriction factors blocking retroviral replication Ann Rev Genet 42 2008 143 163
48. J. Scholler, T.L. Brady, and G. Binder-Scholl Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells Sci Transl Med 4 2012 132ra53
49. F.D. Bushman Retroviral integration and human gene therapy J Clin Invest 117 2007 2083 2086
50. D. Lindemann, and A. Rethwilm Foamy virus biology and its application for vector development Viruses 3 2011 561 585
51. E.E. Perez, J. Wang, and J.C. Miller Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases Nat Biotechnol 26 2008 808 816
52. A.J. Dupuy, K. Akagi, D.A. Largaespada, N.G. Copeland, and N.A. Jenkins Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system Nature 436 2005 221 226
53. P.B. Hackett, D.A. Largaespada, and L.J.N. Cooper A transposon and transposase system for human application Mol Ther 18 2010 674 683
54. P. Kebriaei, H. Huls, and B. Jena Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies Hum Gene Ther 23 2012 444 450
55. Y. Zhao, Z. Zheng, and C.J. Cohen High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation Mol Ther 13 2006 151 159
56. S.H. Yoon, J.M. Lee, and H.I. Cho Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model Cancer Gene Ther 16 2009 489 497
57. D.A. Mitchell, I. Karikari, and X. Cui Selective modification of antigen-specific T cells by RNA electroporation Hum Gene Ther 19 2008 511 521
58. J. Rowley, A. Monie, C.-F. Hung, and T.-C. Wu Expression of IL-15RA or an IL-15/IL-15RA fusion on CD8+ T cells modifies adoptively transferred T-cell function in cis Eur J Immunol 39 2009 491 506
59. Y. Zhao, E. Moon, and C. Carpenito Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor Cancer Res 70 2010 9053 9061
60. P. Cannon, and C. June Chemokine receptor 5 knockout strategies Curr Opin HIV AIDS 6 2011 74 79
61. D. Reyon, S.Q. Tsai, and C. Khayter FLASH assembly of TALENs for high-throughput genome editing Nat Biotechnol 30 2012 460 465
62. A. Varela-rohena, C. Carpenito, and E.E. Perez Genetic engineering of T cells for adoptive immunotherapy Immunol Res 42 2008 166 181
63. D. Kalamasz, S.A. Long, and R. Taniguchi Optimization of human T-cell expansion ex vivo using magnetic beads conjugated with anti-CD3 and Anti-CD28 antibodies J Immunother 27 2004 405 418
64. M.V. Maus, A.K. Thomas, and D.G.B. Leonard Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB Nat Biotechnol 20 2002 143 148
65. D. Hollyman, J. Stefanski, and M. Przybylowski Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy J Immunother 32 2009 169 180
66. S. Yang, M.E. Dudley, S.A. Rosenberg, and R.A. Morgan A simplified method for the clinical-scale generation of central memory-like CD8+ T cells after transduction with lentiviral vectors encoding antitumor antigen T-cell receptors J Immunother 33 2010 648 658
67. D.L. Porter, B.L. Levine, and N. Bunin A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation Blood 107 2006 1325 1331
68. R.J. O'Reilly, T. Dao, G. Koehne, D. Scheinberg, and E. Doubrovina Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation Semin Immunol 22 2010 162 172
69. A.P. Rapoport, E.A. Stadtmauer, and N. Aqui Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cells Clin Cancer Res 15 2009 4499 4507
70. M.J. Besser, R. Shapira-Frommer, and A.J. Treves Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients Clin Cancer Res 16 2010 2646 2655
71. M.E. Dudley, J.R. Wunderlich, and P.F. Robbins Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes Science 298 2002 850 854
72. K.Q. Tran, J. Zhou, and K.H. Durflinger Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy J Immunother 31 2008 742 751
73. A.M. Leen, A. Christin, and G.D. Myers Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation Blood 114 2009 4283 4292
74. C.U. Louis, K. Straathof, and C.M. Bollard Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma J Immunother 33 2010 983 990
75. V. Appay, D.C. Douek, and D.A. Price CD8+ T cell efficacy in vaccination and disease Nat Med 14 2008 623 628
76. C. Carpenito, M.C. Milone, and R. Hassan Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains Proc Nat Acad Sci U S A 106 2009 3360 3365
77. P. Wong, and E.G. Pamer CD8 T cell responses to infectious pathogens Ann Rev Immunol 21 2003 29 70
78. N. Zhang, and M.J. Bevan CD8(+) T cells: foot soldiers of the immune system Immunity 35 2011 161 168
79. J.C. Sun, and M.J. Bevan Defective CD8 T cell memory following acute infection without CD4 T cell help Science 300 2003 339 342
80. J.C. Sun, M.A. Williams, and M.J. Bevan CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection Nat Immunol 5 2004 927 933
81. R.A. Seder, P.A. Darrah, and M. Roederer T-cell quality in memory and protection: implications for vaccine design Nature reviews. Immunology 8 2008 247 258
82. M.V. Maus, B. Kovacs, and W.W. Kwok Extensive replicative capacity of human central memory T cells J Immunol 172 2004 6675 6683
83. A. Wang, S. Chandran, and S.A. Shah The Stoichiometric Production of IL-2 and IFN- mRNA defines memory T cells that can self-renew after adoptive transfer in humans Sci Transl Med 4 2012 149ra120-149ra120
84. C.A. Klebanoff, L. Gattinoni, and P. Torabi-Parizi Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells Proc Nat Acad Sci U SA 102 2005 9571 9576
85. P. Muranski, A. Boni, and P.A. Antony Tumor-specific Th17-polarized cells eradicate large established melanoma Blood 112 2008 362 373
86. L. Gattinoni, E. Lugli, and Y. Ji A human memory T cell subset with stem cell-like properties Nat Med 17 2011 1290 1297
87. H. Zhang, K.M. Snyder, and M.M. Suhoski 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy J Immunol 179 7 2007 4910 4918
88. M.H. Kershaw, J.A. Westwood, and L.L. Parker A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer Clin Cancer Res 12 2006 6106 6115
89. J.R. Park, D.L. Digiusto, and M. Slovak Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in Patients with neuroblastoma Mol Ther 15 2007 825 833
90. J. Zhou, X. Shen, and J. Huang Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy J Immunol 175 2012 7046 7052
91. H.M. Finney, A.N. Akbar, and D.G. Alastair Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134 and CD137 in series with signals from the TCRz chain J Immunol 172 2004 104 113
92. C. Imai, K. Mihara, and M. Andreansky Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia Leukemia 18 2004 676 684
93. M.A. Pulè, K.C. Straathof, and G. Dotti A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells Mol Ther 12 2005 933 941
94. M.S. Topp, S.R. Riddell, and Y. Akatsuka Restoration of CD28 expression in CD28- CD8+ memory effector T cells reconstitutes antigen-induced IL-2 production J Exp Med 198 2003 947 955
95. M.T. Lotze, J.L. Strausser, and S.A. Rosenberg In vitro growth of cytotoxic human lymphocytes. II. Use of T cell growth factor (TCGF) to clone human T cells J Immunol 124 1980 2972 2978
96. A. Ma, R. Koka, and P. Burkett Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis Ann Rev Immunol 24 2006 657 679
97. L.S. Evans, P.R. Witte, and A.L. Feldhaus Expression of chimeric granulocyte-macrophage colony-stimulating factor/interleukin 2 receptors in human macrophage colony-stimulating factor-dependent growth Hum Gene Ther 10 1999 1941 1951
98. C. Hsu, S.A. Jones, and C.J. Cohen Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene Blood 109 2007 5168 5177
99. N. Rufer Transfer of the human telomerase reverse transcriptase (TERT) gene into T lymphocytes results in extension of replicative potential Blood 98 2001 597 603
100. J. Charo, S.E. Finkelstein, and N. Grewal Bcl-2 overexpression enhances tumor-specific T-cell survival Cancer Res 65 2005 2001 2008
101. Eaton D, Gilham S, O'Neill A, et al Retroviral transduction of human peripheral blood lymphocytes with bcl-x L promotes in vitro lymphocyte survival in proapoptotic conditions. Gene Ther 2002;9:527-35.
102. G. Dotti, B. Savoldo, and M. Pule Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis Blood 105 2005 4677 4684
103. Q. Zhang, X. Yang, and M. Pins Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer Cancer Res 65 2005 1761 1769
104. K. Lacuesta, E. Buza, and H. Hauser Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor J Immunother 29 2006 250 260
105. J.C. Nolz, G.R. Starbeck-Miller, and J.T. Harty Naive, effector and memory CD8 T cell trafficking: parallels and distinctions Immunotherapy 3 2011 1223 1233
106. E.K. Moon, C. Carpenito, and J. Sun Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human t cells expressing a mesothelin-specific chimeric antibody receptor Clin Cancer Res 17 2011 4719 4730
107. H. Harlin, Y. Meng, and A. Peterson Chemokine expression in melanoma metastases associated with Cancer Res 69 2009 3077 3085
108. D.T. Fisher, Q. Chen, and M.M. Appenheimer Hurdles to lymphocyte trafficking in the tumor microenvironment: implications for effective immunotherapy Immunol Invest 35 2006 251 277
109. C. Berger, M.E. Flowers, E.H. Warren, and S.R. Riddell Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation Blood 107 2006 2294 2302
110. M.C. Jensen, L. Popplewell, and L.J. Cooper Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans Biol Blood Marrow Transplantation 16 2010 1245 1256
111. J.L. Davis, M.R. Theoret, and Z. Zheng Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials Clin Cancer Res 16 2010 5852 5861
112. C.H.J. Lamers, R. Willemsen, and Elzakker P. van Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells Blood 117 2011 72 82
113. C.H.J. Lamers, S.C.L. Langeveld, and C.M. Groot-van Ruijven Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo Cancer Immunol Immunother 56 2007 1875 1883
114. Stasi A. Di, S.-K. Tey, and G. Dotti Inducible apoptosis as a safety switch for adoptive cell therapy N Engl J Med 365 2011 1673 1683
115. C. Quintarelli, J.F. Vera, and B. Savoldo Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes Blood 110 2007 2793 2802
116. M. Griffioen, E.H.M. van Egmond, and M.G.D. Kester Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy Haematologica 94 2009 1316 1320
117. H.J. Pegram, J.C. Lee, and E.G. Hayman Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning Blood 119 2012 4133 4141
118. P. Muranski, A. Boni, and C. Wrzesinski Increased intensity lymphodepletion and adoptive immunotherapy - how far can we go? Nat Clin Pract Oncol 3 2006 668 681
119. C. Wrzesinski, and N.P. Restifo Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy Curr Opin Immunol 17 2005 195 201
120. J.H. Machiels, R.T. Reilly, and L.A. Emens Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage- colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice Cancer Res 61 2001 3689 3697
121. M. Obeid, A. Tesniere, and F. Ghiringhelli Calreticulin exposure dictates the immunogenicity of cancer cell death Nat Med 13 2007 54 61
122. J.S. Miller, Y. Soignier, and A. Panoskaltsis-Mortari Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer Blood 105 2005 3051 3057
123. D.L. Porter, R.H. Collins, and C. Hardy Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions Blood 95 2000 1214 1221
124. K.S. Peggs, K. Thomson, and D.P. Hart Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses Blood 103 2004 1548 1556
125. M. Kalos An integrative paradigm to impart quality to correlative science J Transl Med 8 2010 26
126. M. Kalos Biomarkers in T cell therapy clinical trials J Transl Med 9 2011 138
127. J.J. Melenhorst, P. Scheinberg, and P.K. Chattopadhyay High avidity myeloid leukemia-associated antigen-specific CD8+ T cells preferentially reside in the bone marrow Blood 113 2009 2238 2244
128. P.F. Robbins, M.E. Dudley, and J. Wunderlich Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy J Immunol 173 2004 7125 7130
129. D.J. Powell, M.E. Dudley, P.F. Robbins, and S.A. Rosenberg Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy Blood 105 2005 241 250
130. C. Berger, M.C. Jensen, and P.M. Lansdorp Adoptive transfer of effector CD8 + T cells derived from central memory cells establishes persistent T cell memory in primates J Clin Invest 118 2008 294 305
131. J.W. Gratama, and F. Kern Flow cytometric enumeration of antigen-specific T lymphocytes Cytometry Part A 58 2004 79 86
132. P.K. Chattopadhyay, M.R. Betts, and D.A. Price The cytolytic enzymes granyzme A, granzyme B, and perforin: expression patterns, cell distribution, and their relationship to cell maturity and bright CD57 expression J Leukoc Biol 85 2009 88 97
133. C.J. Turtle, H.M. Swanson, N. Fujii, E.H. Estey, and S.R. Riddell A distinct subset of self-renewing human memory CD8+ T cells survives cytotoxic chemotherapy Immunity 31 2009 834 844
134. M.R. Betts, and A. Harari Phenotype and function of protective T cell immune responses in HIV Curr Opin HIVAIDS 3 2008 349 355
135. D. Gaucher, R. Therrien, and N. Kettaf Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses J Exp Med 205 2008 3119 3131
136. G. Makedonas, N. Hutnick, and D. Haney Perforin and IL-2 upregulation define qualitative differences among highly functional virus-specific human CD8 T cells PLoS Pathogens 6 2010 e1000798
137. Y. Lin, H.F. Gallardo, and G.Y. Ku Optimization and validation of a robust human T cell culture method for monitoring phenotypic and polyfunctional antigen- specific CD4 and CD8 T-cell responses Cytotherapy 11 2009 912 922
138. M.A. Suni, and V.C. Maino Flow cytometric analysis of cell signaling proteins A.E. Kalyuzhny, Methods in molecular biology Vol. 717 2011 Springer Science Clifton, NJ 155 169
139. C. Yee, J.A. Thompson, and P. Roche Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo J Exp Med 192 2000 1637 1644
140. D.C. Palmer, C.-C. Chan, and L. Gattinoni Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity Proc Nat Acad Sci U S A 105 2008 8061 8066
141. R.A. Morgan, J.C. Yang, and M. Kitano Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2 Mol Ther 18 2010 843 851
142. R. Brentjens, R. Yeh, Y. Bernal, I. Riviere, and M. Sadelain Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial Mol Ther 18 2010 666 668
143. T.F. Gajewski, J. Louahed, and V.G. Brichard Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy Cancer J 16 2010 399 403
144. D.F. Stroncek, P. Jin, and E. Wang Global transcriptional analysis for biomarker discovery and validation in cancer and hematological malignancy biologic therapies Mol Diagn Ther 13 2009 181 193
145. C. Carpenito, M.C. Milone, and R. Hassan Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains Proc Nat Acad Sci U S A 106 2009 3360 3365
146. R.J. Brentjens, E. Santos, and Y. Nikhamin Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts Clin Cancer Res 13 18 Pt 1 2007 5426 5435
147. B. Savoldo, C.A. Ramos, and E. Liu Brief report CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients J Clin Invest 121 2011 1822 1826
148. J.L. Riley, and C.H. June The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation Blood 105 2005 13 21
149. A. Loskog, V. Giandomenico, and C. Rossig Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells Leukemia 20 2006 1819 1828
150. C.H.J. Lamers, S. Sleijfer, and A.G. Vulto Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience J Clin Oncol 24 2006 e20 e22
151. K. Birkholz, C. Hofmann, and S. Hoyer A fast and robust method to clone and functionally validate T-cell receptors J Immunol Methods 346 2009 45 54
152. S. Seitz, C.K. Schneider, and J. Malotka Reconstitution of paired T cell receptor alpha- and beta-chains from microdissected single cells of human inflammatory tissues Proc Nat Acad Sci U S A 103 2006 12057 12062
153. D.M. Barrett, Y. Zhao, and X. Liu Treatment of Advanced Leukemia in Mice with mRNA Engineered T Cells Hum Gene Ther 22 2011 1575 1586